Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

Search

Top

Pharmalucence, Inc. MA 01821-5729 USA

UEI: SLED_2B048B3593384FA8

Pharmalucence, Inc. MA 01821-5729 USA is a federal contractor, registered under UEI SLED_2B048B3593384FA8. It has been awarded $75,000 in federal contracts. Primary work spans Pharmaceutical Preparation Manufacturing. Top awarding agencies include Department Of Defense.

Contact Information

Registration and classification details

Registration

UEI Code

SLED_2B048B3593384FA8

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

AI Capability Profile

Pharmalucence, Inc. specializes in pharmaceutical and biological product manufacturing, as indicated by their work within the pharmaceutical preparation for humans category. The company has experience supporting the W40M MRC0 West. Their industry focus is centered on NAICS 325412, which encompasse...

Key Performance Metrics

Awards Count

1

All time

Active

0

Currently performing

Completed

0

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency

Department Of Defense$75.0K100%

Awards by NAICS

325412 - Pharmaceutical Preparation Manufacturing$75.0K100%

Awards by Agency Over Time

Awards by Place of Performance

Compete with Pharmalucence, Inc. MA 01821-5729 USA

Track the contractors you bid against, and the work they win

Award history, agency mix, and NAICS coverage for Pharmalucence, Inc. MA 01821-5729 USA

AI-powered matching against your own capabilities and past performance

Teaming and subcontracting signals on every award

Automated alerts when a competitor wins in your market

Join 750+ contractors already using CLEATUS

Open opportunities in Pharmalucence, Inc. MA 01821-5729 USA's top NAICS codes and agencies

Supplier of Red Sealing Compound (NSN 8030015650423)

Defense Logistics Agency

POSTED

DEADLINE

Active Pharmaceutical Ingredient (API) SupplyThis subcontract for Active Pharmaceutical Ingredient (API) Supply involves the synthesis, purification, and bulk delivery of pharmaceutical-grade Benzocaine and Menthol. The provider supports prime contractors fulfilling requirements for the Department of Defense Medical Supply Chain Pharm FSA, ensuring all raw chemical components meet strict USP and ISO manufacturing standards through the use of HPLC purity testing. The performance of this contract is centered at Fort Campbell, Kentucky, under NAICS code 325412. The solicitation was posted on October 19, 2026, with a response deadline of October 26, 2026.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Benzocaine and Menthol Lozenge SupplyThis subcontract involves the manufacture and supply of finished Benzocaine and Menthol lozenges to prime contractors supporting the Department of Defense Medical Supply Chain Pharm FSA. The provider is responsible for producing and quality-testing pharmaceutical lozenges within FDA-compliant facilities adhering to Good Manufacturing Practice standards to ensure all delivered quantities meet strict government specifications. Administrative processes for this requirement are managed through the DLA Internet Bid Board System for quote submissions. The performance of the contract is centered at Fort Campbell, and the procurement falls under NAICS code 325412 for pharmaceutical preparation.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Supply of Moxifloxacin Hydrochloride Tablets (400 MG)This subcontract, managed by the Medical Supply Chain Pharm FSA under the Department of Defense, involves the manufacture and supply of pharmaceutical-grade Moxifloxacin Hydrochloride Tablets (400 MG). The contractor is responsible for providing the antibiotic tablets in 30-count bottles, ensuring all products are sourced or manufactured in accordance with Good Manufacturing Practices and FDA approval and registration requirements. Logistical compliance is critical, as the contract mandates adherence to RP001 DLA Packaging Requirements and the use of climate-controlled storage and transport to maintain product integrity. Performance will take place in FPO 09591, with the primary objective of supporting prime contractors on DLA supply contracts.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Supply of Activated Charcoal, SuspensionThis subcontract, issued by the Medical Supply Chain Pharm FSA under the Department of Defense, requires the provision of activated charcoal in suspension form, identified by NSN 6505012828880. The materials must be delivered to the USS Lewis B Puller ESB 3, with all shipments adhering to strict DLA packaging requirements and technical specifications. The contract falls under NAICS code 325412 and is intended for prime contractors supporting DLA supply operations. Resellers are specifically required to comply with the Non-Manufacturer Rule to ensure eligibility. The performance location is designated as FPO 09591, with a response deadline set for October 26, 2026.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Supply of 4% Chlorhexidine Gluconate Surgical Detergent

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Supply of Bupivacaine and Epinephrine InjectionThis subcontract involves the supply of Bupivacaine and Epinephrine Injection to prime contractors supporting DLA Troop Support medical supply contracts. The provider must deliver end items compliant with NSN 6505-01-189-3973, utilizing pharmaceutical-grade materials and medical-grade packaging. To qualify, the supplier is required to hold all necessary pharmaceutical manufacturing licenses and maintain FDA approval for the specific drug formulation. Managed by the Department of Defense under the Medical Supply Chain Pharm FSA, the contract specifies the delivery of injectable medication quantities as outlined in the award. The performance location is designated as FPO 09591, and the procurement falls under NAICS code 325412.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Isoniazid Tablet Manufacturing

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Tetrahydrozoline Hydrochloride Ophthalmic Solution SupplierThis subcontract involves the supply of Tetrahydrozoline Hydrochloride Ophthalmic Solution, USP (0.05%, 15 ML) to support prime contractors under DLA Troop Support medical supply contracts. The selected provider is responsible for manufacturing or sourcing the pharmaceutical solution in accordance with USP standards, utilizing sterile ophthalmic bottling and packaging. All operations must comply with FDA approval and registration requirements for pharmaceutical manufacturing. The contract is managed by the Department of Defense under the Medical Supply Chain Pharm FSA. Physical deliveries of the ophthalmic solution are to be made to either the prime contractor or the Naval Med Readiness Logistics Command, with the place of performance located in Williamsburg, Virginia.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Supply of Tolnaftate Powder, USP 1%This subcontract through the Department of Defense Medical Supply Chain Pharm FSA involves the supply of Tolnaftate Powder, USP 1%, to prime contractors on DLA Troop Support medical supply contracts. The requirement is for 15 bottles of 45 GM powder, identified by NSN 6505014807897, which must strictly adhere to USP 1% standards and the DLA Master List of Technical and Quality Requirements. Eligible providers must possess the necessary pharmaceutical manufacturing and distribution licenses to fulfill the order. The performance of this contract is designated for FPO 09591, with a response deadline set for October 26, 2026.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

DETERGENT, SURGICAL

Solicitation # SPE2DP-27-T-0122

Solicitation SPE2DP-27-T-0122 is a procurement request by the Defense Logistics Agency for surgical detergent containing 4% chlorhexidine gluconate, identified by NSN 6505-01-101-3759. The requirement is for one 8 oz bottle to be delivered FOB Destination to the USNS ABLE TAGOS 20. The item is FDA regulated and must have a total shelf life of 24 months, with at least 21 months remaining upon delivery to the government. The original required delivery date is October 21, 2026, with a delivery lead time of 20 days after award. The contract mandates strict adherence to Medical Marking Standard No. 1C and DLA packaging requirements RP001. Packaging must be commercial, utilizing sealed unit containers and suitable exterior shipping containers. If the material is deemed hazardous per FED-STD-313, it must follow TQ requirement IP025; otherwise, it must comply with ASTM D3951. Offerors must submit quotes via DIBBS by October 26, 2026, and provide a Safety Data Sheet meeting 29 CFR 1910.1200(g) prior to award. The procurement is subject to destination inspection under FAR 52.246-2 and incorporates the Buy American Act and HUBZone price evaluation preferences. Invoicing and receiving reports must be processed through the Wide Area WorkFlow system.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

TETRAHYDROZOLINE HYDRO

Solicitation # SPE2DP-27-T-0130

Solicitation SPE2DP-27-T-0130 is a fixed-price contract issued by the DLA Troop Support Medical Supply Chain Pharm FSA for the procurement of Tetrahydrozoline Hydrochloride Ophthalmic Solution, USP (NSN 6505-00-139-4600). The requirement consists of one bottle of 0.05 percent, 15 ml solution, to be delivered FOB Destination to the Naval Med Readiness Logistics Cmd in Williamsburg, Virginia, with a required delivery date of October 21, 2026. The item is classified as a Type I (Code Q) item with a non-extendable shelf life of 36 months. The contract mandates strict adherence to commercial packaging standards, requiring sealed unit containers and exterior shipping containers that protect contents from damage. All materials must be marked according to Medical Marking Standard No. 1, which supersedes MIL-STD-129, and preservation must comply with MIL-STD-2073-1E and special packaging instructions MPWN00001. Additionally, the contractor must comply with FDA regulations, the Buy American and Balance of Payments Program, and specific hazardous material labeling requirements under 29 CFR 1910.1200. Inspection and acceptance will occur at the destination point. Invoicing and payment are to be processed electronically through the Wide Area WorkFlow system.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

TOLNAFTATE POWDER

Solicitation # SPE2DP-27-T-0126

Solicitation SPE2DP-27-T-0126 is a fixed-price procurement issued by the DLA Troop Support Medical Supply Chain Pharm FSA for the supply of 15 bottles of Tolnaftate Powder, USP 1%, 45 GM (NSN 6505014807897). The contract requires delivery within 20 days after receipt of order, with an original required delivery date of October 21, 2026. The shipment is destined for the USS Lewis B Puller ESB 3, with both inspection and acceptance occurring at the destination. The item is classified as a Type I (Code Q) item with a non-extendable shelf life of 36 months. Compliance requirements include adherence to the DLA Master List of Technical and Quality Requirements, which takes precedence over ASTM D3951 for commercial packaging. All packaging must be marked and labeled according to MIL-STD-129 and Medical Marking Standard No. 1, with palletization following RP001 requirements. If the material is deemed hazardous per FED-STD-313, it must be packaged according to TQ requirement IP025. Administratively, the contract mandates the use of the Wide Area WorkFlow (WAWF) system for electronic invoicing and requires compliance with the Buy American and Balance of Payments Program, the Berry Amendment, and DFARS 252.204-7012 for safeguarding covered defense information.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

ENROFLOXACIN INJECTION

Solicitation # SPE2DP-27-T-0128

Solicitation SPE2DP-27-T-0128, issued by the DLA Troop Support Medical Supply Chain Pharm FSA, is for the procurement of six units of veterinary Enrofloxacin Injection. This FDA-regulated drug is an intramuscular solution for dogs, formulated at 2.27% (2.5mg/kg) in 20ML doses for managing bacterial pathogens. The item has a non-extendable shelf life of 24 months and requires specific storage conditions: protection from direct sunlight, no freezing, and maintenance at or below 25 degrees Celsius, with permitted excursions up to 40 degrees Celsius. Delivery is set for October 19, 2026, with FOB Destination terms. The shipping destination is the USA Med Mat Ctr EUR in Kaiserslautern, Germany. Packaging must be commercial and compliant with MIL-STD-2073-1E and DLA requirement RP001, while marking must strictly adhere to Medical Marking Standard No. 1, which supersedes MIL-STD-129. The contract incorporates various FAR and DFARS clauses, including those for safeguarding covered defense information, the Buy American Act, and the prohibition of covered defense telecommunications equipment. Invoicing and payment requests must be processed electronically via the Wide Area WorkFlow system.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

CHARCOAL, ACTIVATED, SUS

Solicitation # SPE2DP-27-T-0125

Solicitation SPE2DP-27-T-0125 is a request for quotations from the Defense Logistics Agency for the procurement of activated charcoal suspension, identified by NSN 6505-01-282-8880. The requirement consists of five bottles, each with a volume of 240 ml and a weight of 50 grams. The items must be delivered to the USS Lewis B Puller ESB 3 by October 21, 2026, with a delivery lead time of 20 days. The product has a non-extendable shelf life of 36 months, and no more than five months may have elapsed from the date of manufacture to the date of delivery to the government. Storage must be maintained at a controlled room temperature between 20 and 25 degrees Celsius. Packaging must be commercial and include suitable sealed unit containers and exterior shipping containers to ensure safe delivery. Marking and labeling must adhere to Medical Marking Standard No. 1, superseding MIL-STD-129, and labels must include the NSN, manufacturer and CAGE code, date of manufacture, expiration or retest date, and the contract or lot number. The contract is governed by the DLA Master Solicitation for Automated Simplified Acquisitions Revision 105 and includes various FAR and DFARS clauses covering small business representations, hazardous material identification, and cybersecurity requirements. Inspection and acceptance will take place at the destination. Quotations are due by October 26, 2026, to the DLA Troop Support Medical Supply Chain Pharm FSA.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

ISONIAZID TABLETS

Solicitation # SPE2DP-27-T-0123

Solicitation SPE2DP-27-T-0123 is a fixed-price request for quotations issued by the DLA Troop Support Medical Supply Chain Pharm FSA for the procurement of Isoniazid Tablets, USP, 300 MG. The requirement consists of two CLINs totaling three bottles, with two bottles destined for the USS Lewis B Puller (ESB 3) and one bottle for the USS Kingsville (LCS 36). The items are identified by NSN 6505-00-132-6904 and must be provided in units of 100 tablets per bottle. Delivery is required within 20 days after receipt of order, with an original required delivery date of October 21, 2026, under FOB Destination terms. The drug is FDA regulated and must be stored at medical controlled room temperature with a non-extendable shelf life of 36 months. Packaging must adhere to MIL-STD-129 and Medical Marking Standard No. 1, with non-hazardous materials following ASTM D3951 and hazardous materials following TQ requirement IP025 and FED-STD-313. Palletization must comply with DLA requirement RP001. The contract incorporates various FAR and DFARS clauses, including those regarding the Buy American Act, Berry Amendment, and safeguarding covered defense information. Invoicing and receiving reports must be processed electronically through the Wide Area WorkFlow system.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

MOXIFLOXACIN HYDROCHLO

Solicitation # SPE2DP-27-T-0127

Solicitation SPE2DP-27-T-0127 is a fixed-price procurement by the Defense Logistics Agency for Moxifloxacin Hydrochloride Tablets, 400 MG. The requirement consists of three bottles, with each bottle containing 30 tablets. The product must be stored at controlled room temperature, avoiding high humidity, and is subject to a non-extendable shelf life of 36 months. Delivery is required within 20 days after receipt of order, with an original required delivery date of October 21, 2026. The shipment is designated as FOB Destination, with the final delivery point being the USS Lewis B Puller ESB 3. Compliance requirements include adherence to the DLA Master List of Technical and Quality Requirements, specifically RA001 and RP001 for packaging and procurement. Marking must follow the latest edition of Medical Marking Standard No. 1 and MIL-STD-129. Packaging must comply with ASTM D3951 for non-hazardous materials or TQ requirement IP025 for hazardous materials. The contract incorporates several federal regulations, including the Buy American and Balance of Payments Program, DFARS 252.204-7012 for safeguarding covered defense information, and NAICS code 325412. Invoicing and payment must be processed electronically through the Wide Area WorkFlow system.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

BUPIVACAINE AND EPINEP

Solicitation # SPE2DP-27-T-0124

Solicitation SPE2DP-27-T-0124 is a fixed-price procurement issued by the DLA Troop Support Medical Supply Chain Pharm FSA for the supply of Bupivacaine and Epinephrine Injection (NSN 6505011893973). The required material consists of 0.500 PCT W/V Bupivacaine HCL and 0.005 mg Epinephrine/ML (1:200,000) provided in 1.8 ML cartridges, with a unit of issue consisting of one container of 50 cartridges. The product must be stored at a controlled room temperature between 15 and 30 degrees Celsius and has a total shelf life of 18 months, with a minimum of 15 months remaining at the time of delivery to the first government activity. Delivery is set for the USS Lewis B Puller ESB 3 with a required delivery date of October 21, 2026, and a lead time of 20 days after receipt of order. Shipping is FOB Destination. Packaging must be commercial and sealed in containers capable of protecting the contents from damage, with palletization adhering to DLA packaging requirements. Marking must comply with Medical Marking Standard No. 1, which supersedes MIL-STD-129. The contract incorporates the Buy American and Balance of Payments Program and requires the use of the Wide Area WorkFlow system for electronic invoicing and payment requests.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE